Rice Hall James & Associates LLC Decreases Holdings in Haemonetics Co. (NYSE:HAE)

Rice Hall James & Associates LLC decreased its holdings in Haemonetics Co. (NYSE:HAE) by 0.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,343 shares of the medical instruments supplier’s stock after selling 384 shares during the period. Rice Hall James & Associates LLC owned 0.09% of Haemonetics worth $3,618,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of HAE. FMR LLC increased its stake in shares of Haemonetics by 206.3% in the third quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock worth $62,257,000 after purchasing an additional 521,640 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Haemonetics by 9.5% in the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock worth $337,722,000 after purchasing an additional 363,702 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Haemonetics by 75.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 795,381 shares of the medical instruments supplier’s stock worth $63,933,000 after purchasing an additional 343,214 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in shares of Haemonetics by 29.5% in the third quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock worth $88,433,000 after purchasing an additional 250,833 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Haemonetics by 439.9% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 220,453 shares of the medical instruments supplier’s stock worth $17,720,000 after purchasing an additional 179,621 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on HAE shares. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research note on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price for the company. StockNews.com lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday. Raymond James restated a “strong-buy” rating and issued a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Barrington Research cut their price objective on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Finally, JMP Securities cut their price objective on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $101.67.

Haemonetics Trading Up 2.9 %

Shares of Haemonetics stock opened at $64.14 on Wednesday. Haemonetics Co. has a 1 year low of $58.80 and a 1 year high of $97.97. The firm has a market cap of $3.22 billion, a PE ratio of 25.25, a PEG ratio of 0.98 and a beta of 0.39. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.09. The company has a 50 day simple moving average of $73.77 and a two-hundred day simple moving average of $77.03.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Analysts expect that Haemonetics Co. will post 4.59 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.